BR112022026275A2 - Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso - Google Patents
Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de usoInfo
- Publication number
- BR112022026275A2 BR112022026275A2 BR112022026275A BR112022026275A BR112022026275A2 BR 112022026275 A2 BR112022026275 A2 BR 112022026275A2 BR 112022026275 A BR112022026275 A BR 112022026275A BR 112022026275 A BR112022026275 A BR 112022026275A BR 112022026275 A2 BR112022026275 A2 BR 112022026275A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- diones
- pyridine
- exhibit
- mnk
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046325P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/039982 WO2022006331A2 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibitng mnk inhibition and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026275A2 true BR112022026275A2 (pt) | 2023-03-14 |
Family
ID=79315594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026275A BR112022026275A2 (pt) | 2020-06-30 | 2021-06-30 | Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230286983A1 (https=) |
| EP (1) | EP4171565A4 (https=) |
| JP (1) | JP2023533616A (https=) |
| KR (1) | KR20230041715A (https=) |
| CN (1) | CN116194112A (https=) |
| AU (1) | AU2021300363A1 (https=) |
| BR (1) | BR112022026275A2 (https=) |
| CA (1) | CA3183551A1 (https=) |
| IL (1) | IL299512A (https=) |
| MX (1) | MX2022016516A (https=) |
| WO (1) | WO2022006331A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225747A1 (en) * | 2021-06-30 | 2023-01-05 | 4E Therapeutics, Inc. | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| CN103874496A (zh) * | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017068064A1 (en) * | 2015-10-22 | 2017-04-27 | Selvita S.A. | Pyridone derivatives and their use as kinase inhibitors |
| BR112018008711A2 (pt) * | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2 |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017165908A1 (en) * | 2016-03-31 | 2017-10-05 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| CN113286592A (zh) * | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110256432A (zh) * | 2019-06-27 | 2019-09-20 | 诺沃斯达药业有限公司 | 抑制mnk1和mnk2的多环化合物 |
-
2021
- 2021-06-30 JP JP2023524490A patent/JP2023533616A/ja active Pending
- 2021-06-30 WO PCT/US2021/039982 patent/WO2022006331A2/en not_active Ceased
- 2021-06-30 BR BR112022026275A patent/BR112022026275A2/pt unknown
- 2021-06-30 MX MX2022016516A patent/MX2022016516A/es unknown
- 2021-06-30 CA CA3183551A patent/CA3183551A1/en active Pending
- 2021-06-30 IL IL299512A patent/IL299512A/en unknown
- 2021-06-30 US US18/003,829 patent/US20230286983A1/en active Pending
- 2021-06-30 CN CN202180056845.0A patent/CN116194112A/zh active Pending
- 2021-06-30 KR KR1020237003174A patent/KR20230041715A/ko active Pending
- 2021-06-30 AU AU2021300363A patent/AU2021300363A1/en active Pending
- 2021-06-30 EP EP21831750.1A patent/EP4171565A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183551A1 (en) | 2022-01-06 |
| WO2022006331A3 (en) | 2022-02-10 |
| EP4171565A2 (en) | 2023-05-03 |
| EP4171565A4 (en) | 2024-11-27 |
| CN116194112A (zh) | 2023-05-30 |
| US20230286983A1 (en) | 2023-09-14 |
| MX2022016516A (es) | 2023-03-28 |
| KR20230041715A (ko) | 2023-03-24 |
| WO2022006331A9 (en) | 2022-03-03 |
| JP2023533616A (ja) | 2023-08-03 |
| WO2022006331A8 (en) | 2023-03-16 |
| WO2022006331A2 (en) | 2022-01-06 |
| IL299512A (en) | 2023-02-01 |
| AU2021300363A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000039A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| BR112022008375A2 (pt) | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| CO2023018119A2 (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| BR112022026275A2 (pt) | Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| CO2026001992A2 (es) | Derivados de 2-(3,8-diazabiciclo[3.2.1]octan-3-il)-1,3,5-triazina como inhibidores de kras g12d para el tratamiento del cáncer | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| BR112022025117A2 (pt) | 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| BR112022025012A2 (pt) | Inibidores de quinase de nek7 | |
| BR112023000212A2 (pt) | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 | |
| BR112019007763A2 (pt) | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. |